Figure 8

Biodistribution of free or liposomal DxM-P in adjuvant arthritis. Concentration of DxM in blood (a) (n = 6), synovial membrane (b) (n = 3), spleen (c) (n = 3), and liver (d) (n = 3) at 0.5, 2, 8, 24, and/or 72, 96, and 288 hours after the initial i. v. treatment with free or liposomal DxM-P during the time course of AA (for details see Figure 1). * P ≤ 0.05, ** P ≤ 0.01 vs. AA/DxM-P; all Mann Whitney U-test; administration of free or liposomal DxM-P at the time points 0 hours, 24 hours, and 48 hours.